News & Updates

Temporary interruption of adjuvant endocrine therapy (ET) to allow for pregnancy has demonstrated short-term safety, with no increase in risk of breast cancer events, including distant recurrence, in hormone receptor–positive breast cancer survivors who have completed 18–30 months of adjuvant ET.

The incidence of melanoma and nonmelanoma skin cancer appears to be markedly low among people with vitiligo, as reported in a study.

The 5-HT_2A receptor agonist psilocybin, when taken under medical supervision, may offer a promising approach to treatment of major depressive disorder (MDD) in cancer patients, results of a small phase II study suggest.

Patients who present with second primary melanomas have better survival and thinner lesions than those presenting with single primary melanomas, reveals a study.